# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2013 Earnings Results

**Report date:** 2013-11-05 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2013

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.32%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.40 | N/A | +141.69% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in their current operations and future prospects. They highlighted the strong EPS performance as a key achievement.

**Key quotes:**

> We are pleased with our strong EPS performance this quarter.

> Our focus remains on advancing our pipeline and delivering value.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance significantly exceeded expectations, leading to a 7.32% increase in stock price. This positive reaction reflects investor confidence in the company's ongoing strategies and potential for future growth. However, the lack of revenue data and guidance leaves some uncertainty about overall performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2013_